Skip to main content
. 2020 Aug 13;11(1):258–270. doi: 10.1016/j.apsb.2020.08.001

Figure 5.

Figure 5

The safety evaluation of various formulations. (A) The scheme of safety assay. (B) The maximum tolerated dose (MTD) of various formulations in C57BL/6 mice. (C) Neutrophil levels of various groups after formulations administration. (D) Creatinine (CR) levels of various groups after administration. Data are shown as the mean ± SD, n = 3, ∗∗∗P < 0.001.